Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection
Open Access
- 22 February 2020
- journal article
- research article
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-11
Abstract
Background: Since the introduction of miltefosine (MIL) as first-line therapy in the kala-azar elimination programme in the Indian subcontinent, treatment failure rates have been increasing. Since parasite infectivity and virulence may become altered upon treatment relapse, this laboratory study assessed the phenotypic effects of repeated in vitro and in vivo MIL exposure. Methods: Syngeneic Leishmania donovani lines either or not exposed to MIL were compared for drug susceptibility, rate of promastigote multiplication and metacyclogenesis, macrophage infectivity and behaviour in the sand fly vector, Lutzomyia longipalpis. Results: Promastigotes of both in vitro and in vivo MIL-selected strains displayed a slightly reduced drug susceptibility that was associated with a reduced MIL-accumulation linked to a lower copy number (disomic state) of chromosome 13 harboring the miltefosine transporter (LdMT) gene. In vitro selected promastigotes showed a lower rate of metacyclogenesis whereas the in vivo derived promastigotes displayed a moderately increased growth rate. Repeated MIL exposure did neither influence the parasite load nor metacyclogenesis in the sand fly vector. Conclusions: Recurrent in vitro and in vivo MIL exposure evokes a number of very subtle phenotypic and genotypic changes which could make promastigotes less susceptible to MIL without attaining full resistance. These changes did not significantly impact on infection in the sand fly vector.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (G051812N, 12I0317N, 1189617N)
- Universiteit Antwerpen (TT-ZAPBOF 33049, TOP-BOF 35017)
- Redes de Investigacion Cooperativa (RETICS-FEDER RD16/0027/0010)
This publication has 39 references indexed in Scilit:
- Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stressPLOS Neglected Tropical Diseases, 2017
- Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from IndiaParasites & Vectors, 2017
- Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?Expert Review of Anti-infective Therapy, 2014
- Relapse after Treatment with Miltefosine for Visceral Leishmaniasis Is Associated with Increased Infectivity of the Infecting Leishmania donovani StrainmBio, 2013
- Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or NoncomplianceClinical Infectious Diseases, 2013
- Characterization of an ABCG-Like Transporter from the Protozoan Parasite Leishmania with a Role in Drug Resistance and Transbilayer Lipid MovementAntimicrobial Agents and Chemotherapy, 2008
- A novel ATP-binding cassette transporter, ABCG6 is involved in chemoresistance of LeishmaniaMolecular and Biochemical Parasitology, 2008
- Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivoInternational Journal of Antimicrobial Agents, 2007
- A novel ATP‐binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl‐phospholipidsMolecular Microbiology, 2007
- Combination of Suboptimal Doses of Inhibitors Targeting Different Domains of LtrMDR1 Efficiently Overcomes Resistance of Leishmania spp. to Miltefosine by Inhibiting Drug EffluxAntimicrobial Agents and Chemotherapy, 2006